GORDON C GUNN, MD, FACOG
CONCIERGE PERSONALIZED CARE
GYNECOLOGY • HORMONE THERAPY
INTEGRATIVE MEDICINE

# Is There a Role for Bazedoxifene (BZA) in Breast Cancer Care?

*"My philosophy and goal in the treatment for my patients with breast cancer is focused towards:*

***"Not just treating cancer—but treating the whole patient."***

*Balancing:*

- *Cancer Control*
- *Long-Term Health*
- *Quality of Life "QoL"*

## A Real-World Example of a typical case:

- A 63-year-old woman is diagnosed with a **small (10 mm), low-grade invasive ductal carcinoma of the breast** that is:
  - Hormone receptor positive (ER/PR+)
  - HER2 negative
  - No lymph node involvement
  - Completely removed with surgery (margins cleared)
- This is considered a **low-risk, early-stage breast cancer**.

---

## What Is the Prognosis for This Type of Cancer?

The **good news**: Outcomes are excellent in patients like this:

- 5-year recurrence risk: ~5–8% (with hormone therapy)
- Risk of spread (metastasis): ~2–4%
- Long-term survival: over 90–95%

**Low risk of recurrence** due to several favorable features:

- Small tumor size
- Low grade (slow growing)
- No lymph node involvement
- Strong hormone sensitivity
- Clean surgical margins
- These cancers tend to behave in a **less aggressive, more predictable way**.

---

## ‘Standard of Care’ Treatment Today

After surgery, most patients are advised to receive:

- **Radiation therapy** (to reduce local recurrence) and
- **Hormone-blocking therapy** (usually tamoxifen or similar drugs for 5–10 years)
- Important point: Hormone-blocking therapy treatments work by reducing or blocking estrogen receptors in the breast, because estrogen can potentially fuel these cancers.

### The Trade-Off: *Estrogen Suppression*

While effective, long-term estrogen suppression can lead to:

- Hot flashes
- Bone loss (osteoporosis)
- Mood and cognitive changes
- Reduced quality of life in some women

This raises an important question:

*“Is there a better balance between cancer control and quality of life (QoL)”?*

---

## What Is Bazedoxifene (BZA)?

Bazedoxifene is a medication originally approved for **osteoporosis** in Europe and Japan. It belongs to a class called **SERMs** (Selective Estrogen Receptor Modulators).

### What makes this drug interesting?

It behaves differently in different tissues in the body:

- **Blocks estrogen in breast tissue** (good for cancer)
- **Supports bone health** (like estrogen)
- **Does not stimulate the uterus** (safer than some alternatives)

---

## How Is BZA Different From Tamoxifen?

| Feature | Tamoxifen | Bazedoxifene |
|---|---|---|
| Action | Blocks estrogen receptor | Destroys/degrades receptor |
| Resistance | Can develop | May work even if resistance occurs |
| Uterus | Can stimulate growth | Protective |
| Metabolism | May worsen lipids | Often improves lipid profile |

👉 BZA may act more like a newer class of drugs called **SERDs**, which remove the estrogen receptor entirely rather than just blocking it.

---

## What Have Laboratory Studies Shown?

In lab and animal studies:

- BZA stops growth of breast cancer cells
- Works even in tamoxifen-resistant cancers
- Effective against mutated estrogen receptors
- May reduce the chance of resistance developing

Key advantage: it may work when standard therapies fail.

---

## What About Human Studies?

1. **Treatment of Advanced Breast Cancer**
   BZA has been studied with drugs like **palbociclib**
   Goal: overcome resistance in metastatic disease
2. **Prevention and Early Disease (*PROMISE Study*)**
   Combination of **BZA + estrogen (DuaVee)** used in women with early changes (DCIS)
   Findings:
   - Reduced cancer cell growth markers (Ki-67)
   - Improved symptoms (fewer hot flashes)
   - Maintained QoL (quality of life)
3. **Additional Benefits**
   May reduce **breast density** (a cancer risk marker)
   May improve **cholesterol and metabolic health**

---

## A New Concept: "Tissue-Selective Estrogen Complex"

BZA is part of a newer strategy: **Protect some tissues while blocking others**

When combined with estrogen:

- *Estrogen* helps symptoms (bones, brain, hot flashes)
- *BZA* blocks harmful effects in breast and uterus

This combination is called a **Tissue Selective Estrogen Complex (TSEC)**.

---

## What Does This Mean for Patients?

**Current reality:**

- Standard therapy (tamoxifen, etc.) is **proven and effective**
- It remains the **recommended approach today**

**Emerging Concept:**

Bazedoxifene may offer:

- Effective and improved cancer control compared to tamoxifen
- Definite better quality of life
- Potential benefit in resistant disease
- A more balanced hormonal approach

## Key Takeaways

- Early-stage, hormone-positive breast cancer often has an **excellent prognosis**
- Standard therapy focuses on **blocking estrogen**
- Bazedoxifene is a **promising alternative approach**
- Bazedoxifene is ONLY available in the U.S. in combination with estrogen **(DuaVee)**
- **It may:**
  - Work differently (and possibly better in some cases)
  - Reduce side effects
  - Preserve quality of life
- However, it is still **being studied** and is not yet 'standard of care' replacement for current adjunct hormonal therapies.

---

## Bottom Line

- This is an evolving area of medicine.
- The goal is shifting toward:

  **"Not just treating cancer—but treating the whole patient."**

- Balancing:
  - Cancer control
  - Long-term health
  - Quality of life

## Understanding Your Options

| Category | Traditional Therapy (Tamoxifen) | Bazedoxifene (BZA) |
|---|---|---|
| **How it works** | Blocks estrogen receptor | Removes/degrades receptor |
| **Effect on cancer** | Proven effective | Promising, under study |
| **Resistance over time** | Can develop | May overcome resistance |
| **Hot flashes** | Common | Less (combination therapy) |
| **Bone health** | Can worsen | Supports bone density |
| **Uterine effects** | Can stimulate lining | Neutral or protective |
| **Cholesterol/metabolism** | May worsen | Often improves |
| **Current status** | Standard of care | Emerging option |

**Simple Takeaway**

- **Tamoxifen:** Proven, beneficial, widely used as standard of care
- **Bazedoxifene:** Newer, promising, not standard of care, worthy of consideration

**Gordon C. Gunn M.D.**

References available on request**.** **March 30, 2026**